FDA approved two NMEs in October

FDA approved only two NMEs in October: Jascayd nerandomilast to treat idiopathic pulmonary fibrosis and Lynkuet elinzanetant to treat vasomotor symptoms of menopause.

Boehringer Ingelheim GmbH said Jascayd is the first new IPF treatment in over a decade and the first PDE4B inhibitor approved in the indication. ...